Peregrine Pharmaceuticals Announces the Initiation of Human Antibody Generation Against Two Additional Antigen Targets With Xenerex Biosciences TUSTIN, Calif., Dec 20, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that it has initiated human antibody
Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Similar Characteristics of Chimeric and Human TNT Monoclonal Antibodies TUSTIN, Calif, Dec 17, 2001 (BW HealthWire) -- Study Concludes That Human TNT Antibody Shows Promise for Human Use Peregrine Pharmaceuticals Inc.
Peregrine Announces Quarterly Conference Call TUSTIN, Calif., Dec 17, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) announced today that it will conduct its quarterly conference call on Thursday, Dec. 20 at 11 a.m. (ET). In order to participate in this call, phone
Peregrine Pharmaceuticals Announces It has Agreed Upon the Design of a Phase III Study for Brain Cancer With the FDA; Study Will Treat Patients With Recurrent Glioblastoma Multiforme TUSTIN, Calif., Dec 13, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc.
Peregrine Pharmaceuticals Announces $5.75 Million Investment From Institutional Investors; Company Director Invests in Offering TUSTIN, Calif.--(BW HealthWire)--Nov. 19, 2001-- Proceeds Will Allow Company to Advance Phase III Clinical Trials and Contract Manufacturing Operations Peregrine
Peregrine Announces Image Fusion Data From Phase II Cotara Trial; Data To Be Presented at the Meeting of the World Federation of Neuro-Oncology TUSTIN, Calif.--(BW HealthWire)--Nov. 16, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that image fusion data from its Phase II